Abstract

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.

Keywords

Booster (rocketry)MedicineBooster doseConfidence intervalCoronavirus disease 2019 (COVID-19)ConfoundingInternal medicinePediatricsImmunologyDiseaseInfectious disease (medical specialty)Immunization

Affiliated Institutions

Related Publications

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

Publication Info

Year
2021
Type
article
Volume
385
Issue
15
Pages
1393-1400
Citations
1205
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1205
OpenAlex

Cite This

Barak Mizrahi, Sharon Alroy‐Preis, Nachman Ash et al. (2021). Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. New England Journal of Medicine , 385 (15) , 1393-1400. https://doi.org/10.1056/nejmoa2114255

Identifiers

DOI
10.1056/nejmoa2114255